Symbols / IPSC Stock $2.30 +3.38% Century Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
IPSC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Brent Pfeiffenberger M.B.A., Pharm.D.
Exch · Country NCM · United States
Market Cap 412.46M
Enterprise Value 325.44M
Income -9.58M
Sales 109.16M
FCF (ttm) -97.21M
Book/sh 1.82
Cash/sh 0.65
Employees 78
Insider 10d —
IPO Jun 18, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.33
PEG —
P/S 3.78
P/B 1.26
P/C —
EV/EBITDA -167.84
EV/Sales 2.98
Quick Ratio 5.82
Current Ratio 5.97
Debt/Eq 27.41
LT Debt/Eq —
EPS (ttm) -0.14
EPS next Y -0.53
EPS Growth —
Revenue Growth -100.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-12
ROA -3.26%
ROE -5.98%
ROIC —
Gross Margin 12.36%
Oper. Margin -13.78%
Profit Margin -8.78%
Shs Outstand 179.72M
Shs Float 97.69M
Insider Own 12.83%
Instit Own 58.81%
Short Float 7.15%
Short Ratio 6.70
Short Interest 10.96M
52W High 3.04
vs 52W High -24.51%
52W Low 0.43
vs 52W Low 427.59%
Beta 1.67
Impl. Vol. 15.28%
Rel Volume 0.08
Avg Volume 1.31M
Volume 100.87K
Target (mean) $3.67
Tgt Median $4.00
Tgt Low $2.00
Tgt High $5.00
# Analysts 3
Recom Buy
Prev Close $2.22
Price $2.29
Change 3.38%
About

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.67
Mean price target
2. Current target
$2.30
Latest analyst target
3. DCF / Fair value
$-9.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.30
Low
$2.00
High
$5.00
Mean
$3.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-21 main HC Wainwright & Co. Buy → Buy $5
2026-01-20 main Piper Sandler Overweight → Overweight $4
2025-11-17 down Leerink Partners Outperform → Market Perform $2
2025-05-16 main Chardan Capital Buy → Buy $6
2025-04-03 main HC Wainwright & Co. Buy → Buy $2
2025-03-28 reit Guggenheim Buy → Buy —
2025-03-24 main Chardan Capital Buy → Buy $7
2025-03-21 main Guggenheim Buy → Buy $5
2025-03-20 main Piper Sandler Overweight → Overweight $2
2025-01-22 reit Guggenheim Buy → Buy —
2025-01-22 reit HC Wainwright & Co. Buy → Buy $5
2024-12-30 main Piper Sandler Overweight → Overweight $4
2024-11-07 main Chardan Capital Buy → Buy $11
2024-11-06 main HC Wainwright & Co. Buy → Buy $5
2024-08-15 main HC Wainwright & Co. Buy → Buy $9
2024-06-17 main Piper Sandler Overweight → Overweight $12
2024-06-04 reit HC Wainwright & Co. Buy → Buy $11
2024-05-10 main HC Wainwright & Co. Buy → Buy $11
2024-04-12 reit Piper Sandler Overweight → Overweight $9
2024-03-15 main Canaccord Genuity Buy → Buy $24
News
RSS: Latest IPSC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-12 RUSSOTTI GREGORY Chief Technology Officer — 10,076 $2.55 $25,684
2026-03-12 CARR DOUGLAS Officer — 7,043 $2.55 $17,953
2026-03-09 RUSSOTTI GREGORY Chief Technology Officer — 479 $2.54 $1,215
2026-03-09 CARR DOUGLAS Officer — 247 $2.54 $626
2026-02-03 CARR DOUGLAS Officer — 323 $1.82 $589
2026-02-02 RUSSOTTI GREGORY Chief Technology Officer — 135,000 $0.00 $0
2026-02-02 PFEIFFENBERGER BRENT Chief Executive Officer — 475,000 $0.00 $0
2026-02-02 COWAN CHAD Officer — 135,000 $0.00 $0
2026-02-02 CARR DOUGLAS Officer — 110,000 $0.00 $0
2025-12-22 COWAN CHAD Officer — 58,060 $0.85 $49,252
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
109.16
+1556.76%
6.59
+194.81%
2.23
-57.01%
5.20
Operating Revenue
109.16
+1556.76%
6.59
+194.81%
2.23
-57.01%
5.20
Operating Expense
119.67
-14.76%
140.40
+10.19%
127.42
-1.25%
129.03
Research And Development
95.67
-10.80%
107.24
+15.68%
92.71
-4.59%
97.17
Selling General And Administration
24.00
-27.60%
33.16
-4.47%
34.71
+8.94%
31.86
General And Administrative Expense
24.00
-27.60%
33.16
-4.47%
34.71
+8.94%
31.86
Other Gand A
24.00
-27.60%
33.16
-4.47%
34.71
+8.94%
31.86
Total Expenses
119.67
-14.76%
140.40
+10.19%
127.42
-1.25%
129.03
Operating Income
-10.51
+92.15%
-133.81
-6.89%
-125.18
-1.09%
-123.83
Total Operating Income As Reported
-17.27
+87.50%
-138.14
+5.74%
-146.55
-9.50%
-133.83
EBITDA
2.60
+102.15%
-120.51
+0.58%
-121.21
-0.01%
-121.20
Normalized EBITDA
9.36
+108.05%
-116.18
-16.36%
-99.84
+10.21%
-111.20
Reconciled Depreciation
13.10
-1.53%
13.30
+1.99%
13.04
+54.55%
8.44
EBIT
-10.51
+92.15%
-133.81
+0.33%
-134.25
-3.56%
-129.64
Total Unusual Items
-6.76
-56.30%
-4.33
+79.75%
-21.36
-113.65%
-10.00
Total Unusual Items Excluding Goodwill
-6.76
-56.30%
-4.33
+79.75%
-21.36
-113.65%
-10.00
Special Income Charges
-6.76
-56.30%
-4.33
+79.75%
-21.36
-113.65%
-10.00
Other Special Charges
—
—
5.00
-50.00%
10.00
Impairment Of Capital Assets
6.76
+56.30%
4.33
-73.56%
16.36
0.00
Net Income
-9.58
+92.43%
-126.57
+7.40%
-136.67
-4.38%
-130.93
Pretax Income
-9.65
+92.27%
-124.78
+7.43%
-134.79
-3.02%
-130.84
Net Non Operating Interest Income Expense
7.35
-43.52%
13.01
+7.17%
12.14
+305.92%
2.99
Interest Expense Non Operating
—
0.00
-100.00%
0.54
-55.00%
1.20
Net Interest Income
7.35
-43.52%
13.01
+7.17%
12.14
+305.92%
2.99
Interest Expense
—
0.00
-100.00%
0.54
-55.00%
1.20
Interest Income Non Operating
7.35
-43.52%
13.01
+2.60%
12.68
+186.81%
4.42
Interest Income
7.35
-43.52%
13.01
+2.60%
12.68
+186.81%
4.42
Other Income Expense
-6.49
-63.30%
-3.97
+81.73%
-21.75
-117.48%
-10.00
Other Non Operating Income Expenses
0.28
-22.32%
0.35
+192.43%
-0.38
-108.67%
4.42
Tax Provision
-0.07
-103.80%
1.79
-4.84%
1.88
+1967.03%
0.09
Tax Rate For Calcs
0.00
-96.67%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
-0.05
+94.79%
-0.91
+79.75%
-4.49
0.00
Net Income Including Noncontrolling Interests
-9.58
+92.43%
-126.57
+7.40%
-136.67
-4.38%
-130.93
Net Income From Continuing Operation Net Minority Interest
-9.58
+92.43%
-126.57
+7.40%
-136.67
-4.38%
-130.93
Net Income From Continuing And Discontinued Operation
-9.58
+92.43%
-126.57
+7.40%
-136.67
-4.38%
-130.93
Net Income Continuous Operations
-9.58
+92.43%
-126.57
+7.40%
-136.67
-4.38%
-130.93
Normalized Income
-2.86
+97.67%
-123.15
-2.80%
-119.79
+0.94%
-120.93
Net Income Common Stockholders
-9.58
+92.43%
-126.57
+7.40%
-136.67
-4.38%
-130.93
Diluted EPS
—
-1.61
+30.00%
-2.30
-1.32%
-2.27
Basic EPS
—
-1.61
+30.00%
-2.30
-1.32%
-2.27
Basic Average Shares
—
78.65
+32.60%
59.31
+2.70%
57.76
Diluted Average Shares
—
78.65
+32.60%
59.31
+2.70%
57.76
Diluted NI Availto Com Stockholders
-9.58
+92.43%
-126.57
+7.40%
-136.67
-4.38%
-130.93
Total Other Finance Cost
—
—
—
0.23
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
223.70
-36.67%
353.22
-2.07%
360.69
-25.87%
486.54
Current Assets
120.77
-37.76%
194.05
+9.64%
176.99
-44.64%
319.72
Cash Cash Equivalents And Short Term Investments
117.11
-38.13%
189.29
+9.58%
172.74
-45.25%
315.50
Cash And Cash Equivalents
61.85
+5.84%
58.44
+23.49%
47.32
-43.84%
84.27
Other Short Term Investments
55.26
-57.77%
130.85
+4.34%
125.41
-45.76%
231.23
Receivables
0.67
-56.12%
1.52
-31.99%
2.23
+186.54%
0.78
Other Receivables
—
—
0.01
-98.08%
0.78
Taxes Receivable
0.27
+3.01%
0.27
-59.08%
0.65
0.00
Accrued Interest Receivable
0.39
-68.66%
1.25
-20.13%
1.57
0.00
Prepaid Assets
1.25
-47.37%
2.38
+135.54%
1.01
-44.08%
1.81
Restricted Cash
0.80
0.00
0.00
-100.00%
0.22
Other Current Assets
0.94
+8.95%
0.86
-14.94%
1.01
-28.65%
1.42
Total Non Current Assets
102.94
-35.33%
159.16
-13.35%
183.70
+10.11%
166.82
Net PPE
66.17
-27.17%
90.85
-1.34%
92.08
-17.59%
111.73
Gross PPE
114.77
-9.57%
126.91
+10.43%
114.92
-8.35%
125.39
Accumulated Depreciation
-48.60
-34.78%
-36.06
-57.89%
-22.84
-67.25%
-13.65
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
20.32
-38.14%
32.85
+34.97%
24.34
-27.63%
33.62
Construction In Progress
0.10
+8.25%
0.10
-21.77%
0.12
-99.11%
14.00
Other Properties
32.70
+0.96%
32.38
+9.42%
29.60
+2.73%
28.81
Leases
61.65
+0.11%
61.58
+1.17%
60.86
+24.33%
48.95
Goodwill And Other Intangible Assets
34.20
+0.00%
34.20
0.00
—
Other Intangible Assets
34.20
+0.00%
34.20
—
—
Investments And Advances
0.00
-100.00%
30.82
-65.41%
89.10
+71.82%
51.85
Non Current Prepaid Assets
0.21
-60.04%
0.53
-2.40%
0.54
-57.06%
1.26
Other Non Current Assets
2.36
-14.90%
2.77
+40.07%
1.98
+0.00%
1.98
Total Liabilities Net Minority Interest
64.77
-66.24%
191.85
+9.04%
175.94
-4.28%
183.81
Current Liabilities
20.23
-84.42%
129.78
+627.23%
17.85
-40.15%
29.82
Payables And Accrued Expenses
13.12
-15.82%
15.59
+37.38%
11.35
-22.18%
14.58
Payables
4.77
+55.22%
3.08
+12.19%
2.74
-49.74%
5.45
Accounts Payable
4.77
+55.22%
3.08
+12.19%
2.74
-49.74%
5.45
Current Accrued Expenses
8.35
-33.27%
12.52
+45.40%
8.61
-5.72%
9.13
Current Debt And Capital Lease Obligation
3.32
-31.75%
4.87
+221.88%
1.51
-78.31%
6.98
Current Debt
—
—
—
6.50
Other Current Borrowings
—
—
—
6.50
Current Capital Lease Obligation
3.32
-31.75%
4.87
+221.88%
1.51
+218.53%
0.47
Current Deferred Liabilities
0.00
-100.00%
109.16
+2396.89%
4.37
-38.89%
7.15
Current Deferred Revenue
0.00
-100.00%
109.16
+2396.89%
4.37
-38.89%
7.15
Other Current Liabilities
3.78
+2305.73%
0.16
-74.35%
0.61
-44.46%
1.10
Total Non Current Liabilities Net Minority Interest
44.54
-28.24%
62.07
-60.74%
158.09
+2.67%
153.99
Long Term Debt And Capital Lease Obligation
40.24
-17.81%
48.96
+4.93%
46.66
+9.95%
42.44
Long Term Debt
—
—
—
3.74
Long Term Capital Lease Obligation
40.24
-17.81%
48.96
+4.93%
46.66
+20.57%
38.70
Non Current Deferred Liabilities
4.30
-1.67%
4.37
-96.07%
111.38
+0.49%
110.83
Non Current Deferred Revenue
—
0.00
-100.00%
111.38
+0.49%
110.83
Non Current Deferred Taxes Liabilities
4.30
-1.67%
4.37
0.00
—
Other Non Current Liabilities
—
8.74
+15503.57%
0.06
-92.20%
0.72
Stockholders Equity
158.94
-1.50%
161.36
-12.66%
184.75
-38.97%
302.74
Common Stock Equity
158.94
-1.50%
161.36
-12.66%
184.75
-38.97%
302.74
Capital Stock
0.01
+0.00%
0.01
+50.00%
0.01
+0.00%
0.01
Common Stock
0.01
+0.00%
0.01
+50.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
87.52
+1.96%
85.84
+42.26%
60.34
+3.18%
58.47
Ordinary Shares Number
87.52
+1.96%
85.84
+42.26%
60.34
+3.18%
58.47
Additional Paid In Capital
950.81
+0.79%
943.37
+12.25%
840.41
+1.96%
824.29
Retained Earnings
-791.92
-1.22%
-782.34
-19.30%
-655.77
-26.33%
-519.10
Gains Losses Not Affecting Retained Earnings
0.03
-90.74%
0.32
+200.00%
0.11
+104.39%
-2.46
Other Equity Adjustments
0.03
-90.74%
0.32
+200.00%
0.11
+104.39%
-2.46
Total Equity Gross Minority Interest
158.94
-1.50%
161.36
-12.66%
184.75
-38.97%
302.74
Total Capitalization
158.94
-1.50%
161.36
-12.66%
184.75
-39.72%
306.48
Working Capital
100.54
+56.44%
64.27
-59.62%
159.15
-45.10%
289.90
Invested Capital
158.94
-1.50%
161.36
-12.66%
184.75
-40.97%
312.98
Total Debt
43.56
-19.07%
53.83
+11.75%
48.17
-2.52%
49.41
Capital Lease Obligations
43.56
-19.07%
53.83
+11.75%
48.17
+22.97%
39.17
Net Tangible Assets
124.74
-1.91%
127.16
-31.17%
184.75
-38.97%
302.74
Tangible Book Value
124.74
-1.91%
127.16
-31.17%
184.75
-38.97%
302.74
Available For Sale Securities
—
30.82
-65.41%
89.10
+71.82%
51.85
Interest Payable
—
—
0.00
-100.00%
0.12
Investmentin Financial Assets
0.00
-100.00%
30.82
-65.41%
89.10
+71.82%
51.85
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-103.88
+5.68%
-110.14
-24.66%
-88.35
-728.72%
14.05
Cash Flow From Continuing Operating Activities
-103.88
+5.68%
-110.14
-24.66%
-88.35
-728.72%
14.05
Net Income From Continuing Operations
-9.58
+92.43%
-126.57
+7.40%
-136.67
-4.38%
-130.93
Depreciation Amortization Depletion
13.10
-1.53%
13.30
+1.99%
13.04
+54.55%
8.44
Depreciation
13.10
-1.53%
13.30
+1.99%
13.04
+54.55%
8.44
Depreciation And Amortization
13.10
-1.53%
13.30
+1.99%
13.04
+54.55%
8.44
Other Non Cash Items
-4.02
-501.35%
-0.67
+39.38%
-1.10
-157.10%
1.93
Stock Based Compensation
6.84
-46.09%
12.69
-13.23%
14.62
+37.05%
10.67
Asset Impairment Charge
6.76
+56.30%
4.33
-73.56%
16.36
0.00
Deferred Tax
-0.07
-108.39%
0.87
0.00
—
Deferred Income Tax
-0.07
-108.39%
0.87
0.00
—
Change In Working Capital
-114.55
-1134.67%
-9.28
-198.91%
9.38
-92.43%
123.94
Change In Prepaid Assets
2.34
+331.31%
0.54
-18.59%
0.67
-35.12%
1.03
Change In Payables And Accrued Expense
-2.75
-2169.92%
0.13
+104.30%
-3.09
-271.96%
-0.83
Change In Accrued Expense
-4.32
-369.35%
1.60
+319.45%
-0.73
-118.45%
3.96
Change In Payable
1.56
+206.33%
-1.47
+37.78%
-2.36
+50.69%
-4.79
Change In Account Payable
1.56
+206.33%
-1.47
+37.78%
-2.36
+50.69%
-4.79
Change In Other Working Capital
-109.16
-1556.76%
-6.59
-227.00%
-2.02
-101.70%
118.49
Change In Other Current Liabilities
-4.98
-47.93%
-3.37
-124.35%
13.82
+162.82%
5.26
Investing Cash Flow
107.50
+126.40%
47.48
-22.33%
61.13
+565.66%
-13.13
Cash Flow From Continuing Investing Activities
107.50
+126.40%
47.48
-22.33%
61.13
+565.66%
-13.13
Net PPE Purchase And Sale
-0.85
-450.65%
-0.15
+98.88%
-13.74
+55.12%
-30.60
Purchase Of PPE
-0.85
-450.65%
-0.15
+98.88%
-13.74
+55.12%
-30.60
Capital Expenditure
-0.85
-450.65%
-0.15
+98.88%
-13.74
+55.12%
-30.60
Net Investment Purchase And Sale
108.35
+89.28%
57.24
-23.54%
74.87
+328.40%
17.48
Purchase Of Investment
-51.17
+57.19%
-119.55
+42.81%
-209.03
+17.70%
-254.00
Sale Of Investment
159.52
-9.77%
176.79
-37.73%
283.90
+4.58%
271.48
Net Business Purchase And Sale
0.00
+100.00%
-9.61
0.00
—
Purchase Of Business
0.00
+100.00%
-9.61
0.00
—
Financing Cash Flow
0.17
-99.77%
74.56
+866.71%
-9.72
-135.81%
27.16
Cash Flow From Continuing Financing Activities
0.17
-99.77%
74.56
+866.71%
-9.72
-135.81%
27.16
Net Issuance Payments Of Debt
—
0.00
+100.00%
-10.24
0.00
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
0.00
+100.00%
-10.24
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
0.00
+100.00%
-10.24
0.00
Net Long Term Debt Issuance
—
0.00
+100.00%
-10.24
0.00
Net Common Stock Issuance
0.17
-99.77%
74.56
+14350.19%
0.52
-98.10%
27.16
Proceeds From Stock Option Exercised
—
—
—
0.00
Net Other Financing Charges
—
—
—
—
Changes In Cash
3.80
-68.11%
11.91
+132.24%
-36.94
-231.55%
28.08
Beginning Cash Position
61.21
+24.16%
49.30
-42.83%
86.24
+48.28%
58.16
End Cash Position
65.01
+6.20%
61.21
+24.16%
49.30
-42.83%
86.24
Free Cash Flow
-104.72
+5.05%
-110.29
-8.04%
-102.08
-516.75%
-16.55
Income Tax Paid Supplemental Data
0.00
-100.00%
0.50
-83.88%
3.11
+183.23%
1.10
Amortization Of Securities
-2.36
+51.02%
-4.81
-20.78%
-3.98
0.00
Common Stock Issuance
0.17
-99.77%
74.56
+14350.19%
0.52
-98.10%
27.16
Issuance Of Capital Stock
0.17
-99.77%
74.56
+14350.19%
0.52
-98.10%
27.16
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category